<生产厂家价格>

羟乙膦酸钠

羟乙膦酸钠用途

阿替膦酸二钠是一种口服和静脉注射活性双膦酸盐。阿替膦酸二钠抑制骨吸收,减少动脉钙化,可用于骨质疏松症研究。依替膦酸二钠具有抗癌活性。阿替膦酸二钠是一种螯合剂,可用于去除水中的重金属[1][2][3][4]。

羟乙膦酸钠名称

[ CAS 号 ]:
7414-83-7

[ 中文名 ]:
依替膦酸钠

[ 英文名 ]:
Etidronate disodium

[中文别名 ]:

[英文别名 ]:

EINECS 231-025-7
Disodium Etidronate Hydrate
MFCD00152567
Didronel
Etidronate disodium
disodium etidronate
Disodium (1-hydroxyethylidene)diphosphonate
Disodium 1-hydroxyethylidene phosphonate

羟乙膦酸钠生物活性

[ 描述 ]:

[ 相关类别 ]:

信号通路 >> 细胞凋亡 >> 细胞凋亡

研究领域 >> 癌症

研究领域 >> 代谢疾病

[体外研究]

依替膦酸二钠(10 mM,24 h)显示出细胞毒性,导致S期人群减少,G2/M人群增加,诱导MCF-7细胞中的p53突变[3]。依替膦酸(100 nM,24 h)二钠诱导破骨细胞凋亡,其表现出凋亡特征,包括染色质凝聚以及通过荧光显微镜检测到的细胞和核形态的改变[5]。

[参考文献]

[1]. Dunn CJ, et al. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994 Dec;5(6):446-74.

[2]. Ariyoshi T, et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006;26(4):215-22.

[3]. Zhou Y, et al. Cytotoxicity of etidronic acid to human breast cancer cells. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-87-92.

[4]. Zhu S, et al. In-Depth Study of Heavy Metal Removal by an Etidronic Acid-Functionalized Layered Double Hydroxide. ACS Appl Mater Interfaces. 2022 Feb 9;14(5):7450-7463.

[5]. Kameda T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med. 1997 Aug 18;186(4):489-95.

羟乙膦酸钠物理化学性质

[ 沸点 ]:
578.8ºC at 760 mmHg

[ 熔点 ]:
> 300ºC

[ 分子式 ]:
C₂H₆Na₂O₇P₂

[ 分子量 ]:
249.992

[ 闪点 ]:
303.8ºC

[ 精确质量 ]:
249.938416

[ PSA ]:
160.57000

[ 外观性状 ]:
白色结晶粉末

[ 储存条件 ]:
2-8°C

[ 水溶解性 ]:
H2O: 26 mg/mL | Soluble in water (26 mg/ml).

羟乙膦酸钠MSDS

详细MSDS(安全技术说明书)

羟乙膦酸钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SZ8562240

CHEMICAL NAME :: Phosphonic acid, (1-hydroxyethylidene)di-, disodium salt

CAS REGISTRY NUMBER :: 7414-83-7

LAST UPDATED :: 199806

DATA ITEMS CITED :: 22

MOLECULAR FORMULA :: C2-H6-O7-P2.2Na

MOLECULAR WEIGHT :: 250.00

WISWESSER LINE NOTATION :: QPQOYQ1OPQQ &-NA- 2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 588 mg/kg/28W-I

TOXIC EFFECTS :: Musculoskeletal - osteomalacia Musculoskeletal - other changes

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1340 mg/kg

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in both tubules and glomeruli

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 372 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - chromodacryorrhea Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 73 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - convulsions or effect on seizure threshold Kidney, Ureter, Bladder - other changes

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1900 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 260 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 49 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - ataxia Gastrointestinal - nausea or vomiting

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 32 mg/kg

TOXIC EFFECTS :: Cardiac - arrhythmias (including changes in conduction) Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 581 mg/kg

TOXIC EFFECTS :: Gastrointestinal - hypermotility, diarrhea Kidney, Ureter, Bladder - interstitial nephritis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72800 mg/kg/26W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in both tubules and glomeruli Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - changes in calcium

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 14560 mg/kg/13W-C

TOXIC EFFECTS :: Endocrine - other changes Blood - other changes Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 14560 mg/kg/52W-I

TOXIC EFFECTS :: Behavioral - ataxia Kidney, Ureter, Bladder - changes in bladder weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphokinase

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - live birth index (measured after birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 5500 mg/kg

SEX/DURATION :: female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 86 gm/kg

SEX/DURATION :: male 9 week(s) pre-mating female 2 week(s) pre-mating female 1-7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 11 gm/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - live birth index (measured after birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 7800 mg/kg

SEX/DURATION :: female 17-22 day(s) after conception lactating female 20 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1500 ug/kg

SEX/DURATION :: female 2-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TYPE OF TEST :: Cytogenetic analysis

TEST SYSTEM :: Rodent - hamster Ovary

DOSE/DURATION :: 1 mmol/L

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 23,1343,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X2888 No. of Facilities: 78 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 1099 (estimated)

羟乙膦酸钠安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302

[ 警示性声明 ]:
P301 + P312 + P330

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
R22

[ 安全声明 (欧洲) ]:
36/37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
1

[ RTECS号 ]:
SZ8562240

羟乙膦酸钠制备

用羟基亚乙二磷酸与氢氧化钠水溶液中和，喷雾干燥而得。

羟乙膦酸钠文献

Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.

Biochim. Biophys. Acta 1841(7) , 977-86, (2014)

2,3-Oxidosqualene is an intermediate in cholesterol biosynthesis and 2,3:22,23-dioxidosqualene act as the substrate for an alternative pathway that produces 24(S),25-epoxycholesterol which effects cho...

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

Lancet Oncol. 15(13) , 1460-8, (2014)

Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed effectiveness of oral risedronate for preventi...

A novel automated hydrophilic interaction liquid chromatography method using diode-array detector/electrospray ionization tandem mass spectrometry for analysis of sodium risedronate and related degradation products in pharmaceuticals

J. Chromatogr. A. 1365 , 131-9, (2014)

• HPLC fused core technology to analyze SR and its degradation products. • Stress test studies on raw material, finished products and placebos. • No interference of the complex matrices (new pharmaceu...

更多文献